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Breast cancer, cdk4/6 i nhi bi tors, palboci cli b Breast cancer (BC) i s the by a majori ty cancer i n women. Despi te the numerous therapeuti c opti ons at our di sposal, i t sti ll remai ns i ncurable, earni ng i t the notori ous reputati on of bei ng the second most common cause of cancer death i n western populati on, followi ng lung cancer (1) . BC i s a heterogenous di sease and i t has vari ety of subgroups accordi ng to cli ni cal, pathologi cal and molecular features (2) . Approxi mately 80% of all BC cases are estrogen receptor-posi ti ve (ER+) /human epi dermal growth factor receptor 2 negati ve (HER2-). Accordi ng to current gui deli nes, sequenti al endocri ne therapy (ET) i s the mai n treatment recommendati on for premenopausal and postmenopausal women wi th ER+/ HER2-stage 4 BC (except for extensi ve vi sceral i nvolvement) (3, 4) . Unfortunately, resi stance to ET (acqui red or de novo) wi ll develop i n the vast majori ty of these cases duri ng therapy (5) . Cycli n dependent ki nases and mammali an target of rapamyci n (mTOR) si gnali ng pathways are the mai n mechani sm of resi stance to ET (6) . Currently, the most commonly recommended therapeuti c opti ons to overcome ET resi stance are mTOR i nhi bi ti on (everoli mus) and CDK4/6 i nhi bi ti on (palboci cli b,abemaci cli b and ri boci cli b) (7) (8) (9) . Combi nati on of CDK4/6 i nhi bi tors wi th ET i n start two seri es of treatment have been wi dely accepted as the standard treatment for ER+ MBC pati ents (10) (11) (12) . However, the acti vi ty of CDK4/6 i nhi bi tors i n MBC pati ents progressi ng after multi ple treatment li nes i s not well known. In thi s multi -center retrospecti ve study we report on the acti vi ty and safety of a CDK4/6 i nhi bi tor (palboci cli b) for pati ents who had fai led at least three li nes of treatment for ER+/ MBC.
Methods
In thi s retrospecti ve observati onal cohort study, between 14 September 2015 and 14 March 2019, we i ncluded 43 pati ents from di fferent medi cal oncology cli ni cs i n Turkey. Cli ni c whom were gi ven palboci cli b after at least three li nes of systemi c treatment for ER+ and HER2-negati ve MBC (confi rmed at di agnosi s or on a metastati c lesi on). Pati ents usi ng fulvestrant or aromatase i nhi bi tors wi th palboci cli b were accepted for study. Ini ti ally defi ned date of fi rst drug i ntake. All pati ents provi ded si gned i nformed consent, and ethi cal approval was gi ven by our ethi cal commi ttee (Date: 12.09 2019, Number: 2019-14/34). Mai n outcomes of thi s tri al were overall survi val (OS) and progress free survi val (PFS). OS was determi ned from the date of i ni ti ati on of therapy unti l death or last vi si t date. PFS was the ti me wi ndow between the begi nni ng of treatment to radi ologi cal progressi on, death or last vi si t date. We also reported the frequency of adverse events related to therapy (neutropeni a, anemi a, thrombocytopeni a, di arrhea etc...). We i ncluded MBC pati ents whom progressed accordi ng to RECIST Cri teri a despi te at least three li nes of standart therapy. Our exclusi on cri teri a were as follows ; radi otheraphy, surgery or systemi c treatment wi thi n two weeks , past medi cal hi story of cardi ovascular di sease (arryhtmi as i ncludi ng atri al fi bri llati on, torsades de poi ntes, long or short QT i nterval, pri or myocardi al i nfarcti on, coronary artey bypass grafti ng, heart fai lure and pulmonary emboli sm ) , hypersensi ti vi ty of palboci cli b and sui ci dal behavi or.
Statistical Analysis
The data was analyzed usi ng descri pti ve stati sti cal methods. Conti nual vari ables are gi ven i n mean ± standard devi ati on, whi lst categori c vari ables are gi ven i n percentages. Kaplan Mei r curves were performed to determi ne overall survi val and progressi on free-survi val. SPSS v.21 was used to analyze the data and generate graphi cal content.
Results
The medi an age of pati ents was 51 (25 th percenti le 44, 75 th percenti le 58) years. All pati ents were di agnosed wi th mBC and 30 (69.7%) pati ents were i ni ti ally stage I-III. All of them were ER posi ti ve and fi ve (11.6%) ER posi ti ve/PR negati ve. The vast the greater part of our pati ents were pathologi cally classi fi ed as havi ng i nvasi ve ductal carci noma (n=41, 95.3%). All pati ents were gi ven at least three li nes of treatment for mBC, i ncludi ng chemotherapy and endocri ne therapy (ET). For most of the patients adjuvant ET was tamoxifen (n=19, 44.1%), other combinations were as follows; letrozole (n=6, 13.9%) and anastrozole (n=3, 6.9%). Fi ve pati ents (11.6%) had recei ved both a steroi dal and a nonsteroi dal AI. Fulvestrant was used i n 39.5 % (n = 17) pati ents before palboci cli b/AI. Twenty-one premenopausal women had undergone surgi cal or medi cal castrati on as part of combi nati on HT. Only one pati ent had been treated wi th the exemestane/everoli mus combi nati on. Most of our pati ents (55%; n = 23) had recei ved sequenti al mono chemotherapy wi th standard drugs i ncludi ng taxanes, capeci tabi ne, gemci tabi ne and anthracycli nes, whi le a small mi nori ty had recei ved combi nati on chemotherapy regi mens such as capeci tabi ne/docetaxel (XT), fluorouraci l, doxorubi ci n and cyclophosphami de (FAC) or doxorubi ci n/docetaxel (AT) or a combi nati on of both approaches. The baseli ne characteri sti cs of pati ents i n the study cohort were outli ned i n Table 1 . Accordi ng to RECİST cri teri as; No complete response was observed. There were parti al response (PR) i n si x pati ents (13.9%), stable di sease (SD) i n 28 pati ents (65,1%) and progressi ve di sease (PD) i n 9 (21%) pati ents. The di sease control rate was 79% and the objecti ve response rate was 13.9%.The medi an PFS i n our populati on was 7 months (25 th percenti le=4, 75 th percenti le= 10) (Fi gure 1), and the medi an overall survi val was 11 months u n c o r r e c t e d p r o o f (25 th percenti le=6, 75 th percenti le= 19) (Fi gure 2). All deaths i n our study cohort were associ ated wi th di sease progressi on. Although there were some side effects, palbociclib was generally well tolerated, as a result, dose reduction was needed for only 6 (14%) patients. The most common non-hematological side effect was nausea (n=30, 69.7%). Elevated transaminases levels were also frequent (n=25, 58.1%). Grade 3 neutropenia occured in 12 (27.9%) patients and febrile neutropenia was seen in 2 (4%) patients ( Table 2) . Discussion CDK4/6 inhibitors critical step in the abolishment of ET resistance among ER-positive, HER2-negative patients. Many Phase II and III clinical trials have been carried out to investigate the efficacy and safety of CDK4/6 inhibitors among this population (8) (9) (10) (11) . In the PALOMA-1 trial, the median PFS was 20.2 months in letrozole/palbociclib arm whereas 10.2 months in the letrozole/placebo arm (HR: 0.488; 95% CI: 0.319-310.748; p = 0.0004) (13) . Similarly, in the PALOMA-2 trial, median PFS was 24.8 months in palbociclib/letrozole arm and 14.5 months in letrozole/placebo arm (HR: 0.58; 95% CI: 0.46-40.72; p < 0.001) (14) . PALOMA-3 trial was performed to find out the efficacy of palbociclib and fulvestrant combination among 521 HR+/-mBC patients as second line treatment option. Palbociclib-fulvestrant combination improved PFS significantly compared to placebo-fulvestrant arm (9.2 vs 3.8 months, p <0.001) (9) . Another CDK4/6 inhibitor abemaciclib was also tested in second line treatment in MONARCH 2 trial.The results were promising; abemaciclib/fulvestrant combination prolonged PFS significantly (median PFS; 16.4 vs 9.3 monhts , p=0.001) (11) . In spite of the efficiency and reliance of CDK4/6 inhibitors were well investigated among ER-positive, HER2negative patients, there are no large number of phase 3 studies showing efficacy after treatment. Ban et al. published a retrospective analysis of 24 heavily pre-treated ER+/HER2-mBC patients. All patients in their trial received a minimum of four lines of treatment for mBC including chemotherapy and ET. They reported that 58.3% of patients achieved stable disease and median progression-free survival was 4.8 months; median overall survival was 11 months. They reported that grade III neutropenia occurred in 54.1% (n = 13) patients, grade IV neutropenia in 12.5% (n = 3) of patients and grade III thrombocytopenia in 12.5% (n = 3) of patients. The most commonly reported treatment-related nonhematologic adverse events were nausea (12.5%; n = 3). These side effects were consistent with our trial. (15) . In our trial, we achieved more stable patients compared to this trial (65.1% vs 58.3) and our PFS was a bit longer (7 vs 4.8 months ) which may be explained by the use different of treatment lines between trials ( min. 3 lines vs min. 4 lines ) but the overall survival was similar with our study. A recent retrospective analysis also aimed to investigate the role of palbociclib among heavily treated (more than 4 previous CT lines ) mBC patients. They reported the utility of palbociclib among 118 HR positive HER2negative advanced breast cancer patients. Clinical benefit rate was 47.5%, overall response rate 15.8%, median PFS 4.5 months and median OS 15.8 months. In terms of therapeuti c efficacy PFS and response rates were comparible with our results but our results were again favorable. Hematological side effects were consistent with our trial; 89.7% developed neutropenia (grade ≥ 3 in 56.8%), 5.1% experienced febrile neutropenia. However, dose reductions and discontinuation rates were higher in that trial compared to our trial; 48.3% had dose decreases after side effects and 3.4% had palbociclib discontinued due to toxicity. (16) . In summary; our trial adds important information about the use of pabociclib among highly treated HR positive HER2-negative advanced breast cancer patients for literature. We demonstrated a comparable PFS and OS rates among advanced patients in a real life trial, and palbociclib was well tolerated among such a severe patient population except for febrile neutropenia. Main limitation of our study is its retrospective nature and relatively small number of patients. Additionally, we only determined progression free survival and overall survival so we could not get any information about quality of life measures.
Conclusion
We demonstrated that the efficacy of palbociclib among heavily treated HR positive HER2-negative advanced breast cancer patients were comparable and it was generally well tolerated among this population. But, further randomized controlled studies with larger number patients are needed to confirm our findings and define patients who may benefit even in late stage disease. 
